Home
MAZE
MAZE News

Latest MAZE THERAPEUTICS INC (MAZE) News on April 2, 2025

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

GlobeNewswire

2 days ago

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

Investing.com

a month ago

Maze Therapeutics receives positive ratings following recent IPO

Maze Therapeutics doses first subject in Phase II AKD treatment trial

Clinical Trials Arena

2 months ago

Maze Therapeutics doses first subject in Phase II AKD treatment trial

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

GlobeNewswire

2 months ago

Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease

MT Newswires

2 months ago

Maze Therapeutics Prices Upsized IPO at $16 Per Share

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

Bloomberg

2 months ago

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

GlobeNewswire

2 months ago

Maze Therapeutics Announces Pricing of Upsized Initial Public Offering

Metsera, Maze secure combined $415 million in IPOs

BioPharma Dive

2 months ago

Metsera, Maze secure combined $415 million in IPOs

Share on Social Networks: